eTable. The frequency of medication overuse headache*.
| Authors | Country | Age group | Frequency of MOH |
| Castillo et al. (1999) (e2) | Spain | ≥ 14 | 1.2% |
| Wang et al. (2000) (e3) | Taiwan | ≥ 65 | 1.0% |
| Lu et al. (2001) (e4) | Taiwan | ≥ 15 | 1.1% |
| Pascual et al. (2001) – review (e5) | 1.0–1.9% | ||
| Prencipe et al. (2001) (e6) | France | ≥ 65 | 1.7% |
| Colas et al. (2004) (e7) | Spain | ≥ 14 | 1.5% |
| Zwart et al. (2004) (e8) | Norway | ≥ 20 | 0.9–1.0% |
| Dyb et al. (2006) (e9) | Norway | 13–18 | 0.2% |
| Wang et al. (2006) (e10) | Taiwan | 12–14 | 0.3% |
| Wiendels 2006 (e11) | Netherlands | 25–55 | 2.6% |
| Stovner et al.(2007) – review (7) | 0.5–1.0% | ||
| Aaseth et al. (2008. 2009) (e12, e13) | Norway | 30–44 | 1.7% |
| Rueda-Sanchez & Diaz-Martinez (2008) (e14) | Colombia | 18–65 | 4.5% |
| Katzarava et al. (2009) (e15) | Georgia | ≥ 16 | 0.9% |
| Da Silva et al. (2009) (e16) | Brazil | 10–93 | 1.6% |
| Straube et al. (2010) (e17) | Germany | 18–88 | 1.0% |
| Jonsson et al. (2011. 2012) (e18, e19) | Sweden | ≥ 15 | 1.8% |
| Linde et al. (2011) (e20) | Norway | ≥ 20 | 1.0% |
| Lipton et al. (2011) (e21) | USA | 12–17 | 1.0% |
| Ayzenberg et al. (2012) (e22) | Russia | 18–65 | 7.2% |
| Ertas et al. (2012) (e23) | Turkey | 18–65 | 2.1% |
| Hagen et al. (2012) (e24) | Norway | ≥ 20 | 0.8% |
| Shahbeigi et al. (2012) (e25) | Iran | ≥ 10 | 4.9% |
| Yu et al. (2012) (e26) | China | 18–65 | 0.9% |
| Schramm et al. (2013) (e27) | Germany | 18–65 | 0.7% |
| Park et al. (2014) (e28) | South Korea | 19–69 | 0.5% |
| Westergaard et al. (2014. 2016) (e1, e29) | Denmark | ≥ 16 | 1.6% (adj. 1.8%) |
| Kristo ffersen and Lundqvist (2014) – review (e30) | 1.0–2.0% | ||
| Steiner (2014) – editorial (e31) | 1.0–2.0% | ||
| Westergaard et al. (2015) – review (e32) | 0.5–7.2% | ||
| Bravo (2015) – review (e33) | Older patients | 1.0–7.1% | |
| Mbewe et al. (2015) (e34) | Zambia | 18–65 | 12.7% (adj. 7.1%) |
| Kulkarni et al. (2015) (e35) | India | 18–65 | 1.2% |
| Manandhar et al. (2016) (e36) | Nepal | 18–65 | 2.2% |
| Zebenigus et al. (2016) (e37) | Ethiopia | 18–65 | 0.8% (adj. 0.7%) |
| Al-Hashel et al. (2017) (e38) | Kuwait | 18–65 | 2.4% |
| Rastenytė et al. (2017) (e39) | Lithuania | 18–65 | 3.5% (adj. 3.2%) |
| Henning et al. (in press) (e40) | Germany | 18–65 | 0.7% |
| Global Burden of Disease (2015) – review (e41) | worldwide | 0.8% |
* Figures based on the review of Westergaard et al. (2014) (e1) supplemented by data from more recent studies and in part recalculated from new data.adj.: adjusted; MOH: medication overuse headache